You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE Test

Virtual Case Challenges in Spondyloarthritis

  1. A 39-year-old man presents to his primary care provider with severe back pain. Which of the following details below would lead the clinician to consider axial spondyloarthritis (axSpA) as a differential diagnosis?
    Pain is worse only after physical activity
    Pain began suddenly 2 weeks prior
    Pain is worse in the morning and after rest
  2. Which of the following should be included in the regular management and assessment for patients with SpA?
    Assess patient’s pain and fatigue and perform a skin examination
    Palpate joints for tenderness and swelling and order a C-reactive protein (CRP)
    Provide physical therapy
    All of the above
  3. The 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend which first-line treatment(s) for patients with axial PsA who are treatment-naive?
    Tumor necrosis factor (TNF) inhibitors
    Interleukin (IL)-17 inhibitors
    NSAIDs
    Janus kinase (JAK) inhibitor
  4. A 35-year-old man with axSpA continues to have symptoms despite NSAIDs and physical therapy. His clinician starts him on a TNF inhibitor. When he returns at 6 months for follow up, his disease activity has not shown improvement.
    According to the 2019 American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) Guidelines, which of the following drug classes/options is appropriate for his next treatment?
    IL-17 inhibitor or JAK inhibitor
    Biosimilar of first TNF inhibitor
    Methotrexate or sulfasalazine